SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU CRYPTO is trending due to its highly dedicated community's relentless focus on building a real-world, permissionless brand, highlighted by ongoing product launches such as Kendu Spice and significant IRL initiatives. This unwavering commitment and 'Kendu Sendu' mindset are driving widespread bullish sentiment and active conversation across the crypto space.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet (STRK) is drawing attention for its surging ecosystem growth, marked by increasing app revenue, user activity, and Total Value Locked. The community is actively discussing its unique position as a quantum-resistant Layer 2, leveraging advanced ZK-STARK technology to offer Bitcoin staking and a seamless user experience through native Account Abstraction, setting it apart from other scaling solutions.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is currently trending due to recent positive clinical data, including a sustained complete resolution of lung metastasis in a breast cancer patient, and a new NCI grant advancing its prostate cancer immunotherapy. However, community sentiment is sharply divided, with enthusiasm for the scientific breakthroughs tempered by widespread concern over a history of significant stock dilution and reverse splits. Discussions are heavily focused on the implications of recent public offerings and a reverse stock split, as the company seeks to fund its ongoing and promising clinical trials.

The future is now. ZygoSwap a decentralized exchange (DEX) on the BNB Chain, providing a fully optimized and customizable trading for any BNB-listed tokens. Key Features: 1. Lowest swapping and trading fees. 2. $ZYGO holders receive 50% reduced fees on swaps and liquidity provision (no minimum holding required). 3. Zero fees for swapping or trading $ZYGO itself. 4. Ability to swap, buy, trade, and provide liquidity for any token on the BNB Chain. 5. Mobile-friendly interface for seamless on-the-go use. 6. ZSwap liquidity rewards token and staking options for additional earnings.  Benefits: 1. Cost-efficient for frequent traders and liquidity providers due to significantly lower fees. 2. Deflationary, Fees generated are used to buy back and burn $ZYGO &amp; $ZSWAP tokens. 3, Enhanced incentives for $ZYGO holders, including reduced costs and future rewards/staking yields. 4. Rewards for large swaps/buys and community engagement (e.g., airdrops for retweets/follows). 5. Optimized offering faster, cheaper transactions in the BNB Chain DeFi ecosystem.

ZygoSwap

ZygoSwap ($ZSWAP) is gaining significant community traction as users enthusiastically discuss its active development team and the operational ZygoSwap DEX. Many are highlighting its unique 'memetility' and perceived undervaluation as a micro-cap project offering practical utility, such as low-fee swaps. The strong engagement and ongoing building efforts are central to the bullish sentiment circulating within the community.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending after a major bank issued a "Sell" rating, citing concerns over shrinking profit margins despite its strong position in the AI server market. The community is sharply divided, with many viewing the downgrade as strategic manipulation to acquire cheaper shares ahead of anticipated strong earnings. Bulls highlight the company's critical role in AI infrastructure and robust revenue growth, while bears focus on profitability challenges and management's perceived missteps.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is actively debated following its latest earnings, which showcased robust growth in AI-powered solutions like Agentforce but coincided with broader market skepticism towards the software sector's valuation and the impact of AI on traditional licensing. Investors are divided, with many seeing a strong "buy the dip" opportunity after a perceived overreaction and others expressing frustration over the stock's volatility and competition from new AI platforms. The central conversation revolves around whether Salesforce's strategic AI pivot will drive sustained growth despite ongoing headwinds affecting SaaS companies.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is generating significant buzz following a rumored collaboration with POL and its integration with ACH, which the community views as a meaningful expansion of its utility. Investors are actively watching for Dash, an "OG privacy coin," to emulate the strong upward movement seen in Zcash, amidst a broader resurgence of interest in privacy tokens. This has ignited discussions around its technical chart patterns and perceived undervaluation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amidst intense buyout speculation, driven by its established product, promising pipeline, and the biotech sector's active M&A environment. The community is keenly awaiting clarity on the company's strategic future, particularly updates on its AUR200 Phase 2 indications, even as frustration mounts over perceived management silence and recent patent developments.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending due to robust preliminary Q4 results and strong 2026 guidance, highlighted at the JPM Healthcare Conference, reinforcing Briumvi's trajectory towards blockbuster status. The community is buzzing about the drug's best-in-class profile and increasing market share, especially as competitors face setbacks with BTK inhibitors, though some express frustration over persistent stock price manipulation despite strong fundamentals.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is actively discussed amid conflicting narratives, fueled by the viral success of new games on its platform and significant efforts to implement mandatory age verification for chat. This comes as the company faces intensified scrutiny, including multiple state lawsuits over child safety and recent analyst downgrades, sharply dividing community sentiment between growth prospects and platform risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galexxy Holdings, Inc. is a health and wellness company with the mission to bring unique and effective health and wellness products to the global market. It is focused on acquiring wellness companies to expand marketing, distribution channels, and revenues to create shareholder value and broaden consumer access globally. The firm's ownership examples range from Wellbeing Farms LLC (WBF), a Functional Mushroom health supplements production and sales company to eVendco which produces VendGenie, a patent-pending smart ID Kiosk dispensing solution. The company was formerly known as AgTech Global International, Inc. and changed its name to Galexxy Holdings, Inc. in March 2022. Galexxy Holdings was founded on May 9, 2000 and is headquartered in Dana Point, CA.

Galexxy Holdings Inc

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$0.0021
Prev Close	$0.0013
Open	$0.0021
Dividend Yield	0.00%
50-Day Moving Average	$0.0045
Beta	0.57
Avg. Volume	20,268.18
PE Ratio	-0.48

52-Week High	$0.0149
52-Week Low	$0.0013
Market Capitalization	$401,200.00
EPS (Annual)	-$0.011
Price to Book	-0.73
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

GXXY
Galexxy Holdings, Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest GXXY News

GXXYGalexxy Holdings, Inc.